Real world evidence (RWE) refers to data collected outside the context of traditional clinical trials, such as observational studies, registries, and electronic health records. RWE can provide valuable insights into the safety, effectiveness, and real-world use of drugs, and has the potential to transform drug development.
Some of the opportunities of real world evidence in drug development include:
1. Improved patient recruitment: RWE can help identify patient populations that are typically underrepresented in clinical trials, such as elderly patients, patients with multiple comorbidities, and those with rare diseases. This can help improve patient recruitment and enable more representative clinical trials.
2. Enhance clinical trial design: RWE can help inform the design of clinical trials, for example, by identifying appropriate endpoints, understanding patient demographics, and identifying potential confounding factors that need to be accounted for.
Identify safety concerns: RWE can help identify safety concerns that may not have been detected in clinical trials, especially those related to long-term use or rare adverse events. This can help improve post-marketing surveillance and ensure that drugs are used safely in the real world.
3. Better understanding of effectiveness: RWE can provide insights into the effectiveness of drugs in the real world, including how drugs are used in combination with other treatments, and how patient outcomes vary across different subpopulations.
4. Accelerate drug development: By leveraging RWE, drug development timelines can be accelerated as fewer resources are required for clinical trials, making it easier to conduct larger and more complex studies. Additionally, RWE can help optimize the design of clinical trials, reducing the likelihood of failed trials and resulting in faster regulatory approvals.
In summary, real world evidence has the potential to improve drug development in a number of ways, including patient recruitment, clinical trial design, safety monitoring, and accelerating drug development timelines. By leveraging RWE, drug developers can gain a better understanding of how drugs work in the real world, which can ultimately improve patient outcomes.
Share this story...
Real World Evidence (RWE) 101 – Study Designs
RWE 101 - Study Designs Real-world evidence (RWE) studies are becoming increasingly important in healthcare decision-making. There are various study designs used to generate RWE, each with their unique [...]
Real World Evidence (RWE) 101 – Protocol Considerations
RWE 101 - Protocol Considerations Real-world evidence (RWE) study protocols and clinical trial protocols both outline the design and conduct of a study. However, they are distinctly different in [...]
Real World Evidence (RWE) 101 – PASS Approval Requirements
RWE 101 - PASS Approval Requirements Post-authorisation safety studies (PASS) are studies conducted after a medicine has been authorized (licensed) with the goal of acquiring more data about the [...]
Real World Evidence (RWE) 101 – Categories of PASS
RWE 101 - Categories of PASS Real-world evidence (RWE) is the clinical evidence about the usage and potential benefits or risks of a product derived from the analysis of [...]
Real World Evidence (RWE) 101 – Safety Monitoring
RWE 101 - Safety Monitoring Real World Evidence (RWE) complements clinical trials and provides additional insights that are difficult to achieve in controlled environments. Here's why:[1] Sample Size and [...]
Real World Evidence (RWE) 101 – How RWE is Being Used to Support the Treatment of Cancer
RWE 101 - How RWE is Being Used to Support the Treatment of Cancer Real-world evidence (RWE) enhances cancer treatment through providing more comprehensive and personalized patient data. Here [...]







